Cellectisの収益Y / Y
Cellectisの収益Y / Yは何ですか。
Cellectisの収益Y / Yは-53.05%です。
収益Y / Yの定義は何ですか。
過去3年間の年間収益の伸びは、過去3年間で平均した1年間の収益成長率です。
The yearly revenue growth rate is calculated as the percentage change in revenue over the trailing twelve months. For this specific metric, the calculation takes into account a series of the last eight quarterly revenues. The revenue growth is useful for determining the success of the company expanding its main business. Revenue growth of 5% to 10% is usually considered good for large-cap companies. For other companies, a sales growth of over 10% is more desirable.
NASDAQのセクタHealth Careにおける収益Y / Yの企業と比べるCellectis
Cellectisは何をしますか。
cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.
Cellectisと類似の収益y / y
- Medley Capital Corpの収益Y / Yは-53.52%です。
- Hamptonの収益Y / Yは-53.36%です。
- Great World Ltdの収益Y / Yは-53.21%です。
- Nyradaの収益Y / Yは-53.18%です。
- Duibaの収益Y / Yは-53.17%です。
- Silo Pharma Incの収益Y / Yは-53.16%です。
- Cellectisの収益Y / Yは-53.05%です。
- Melstar Information Technologiesの収益Y / Yは-53.01%です。
- Stampede Capitalの収益Y / Yは-53.01%です。
- Stampede Capitalの収益Y / Yは-53.01%です。
- Xcel Brands Incの収益Y / Yは-52.98%です。
- The Lakshmi Vilas Bankの収益Y / Yは-52.88%です。
- KWESST Micro Systemsの収益Y / Yは-52.86%です。